- Investing Ideas
- U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt
U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt
Results
12
Stocks with a return on equity of over 30% and a debt to equity ratio below 1.
12 companies
Gilead Sciences
Market Cap: US$158.0b
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD
US$125.45
7D
3.3%
1Y
16.2%
Illumina
Market Cap: US$24.9b
Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
ILMN
US$159.09
7D
-2.1%
1Y
76.3%
Exelixis
Market Cap: US$13.1b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$52.44
7D
-0.3%
1Y
28.7%
ACADIA Pharmaceuticals
Market Cap: US$3.6b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$21.60
7D
1.6%
1Y
-5.9%
ADMA Biologics
Market Cap: US$2.0b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$8.42
7D
-0.7%
1Y
-53.6%
Innoviva
Market Cap: US$1.7b
Operates as a biopharmaceutical company in the United States and internationally.
INVA
US$22.64
7D
-1.6%
1Y
5.5%
Theravance Biopharma
Market Cap: US$860.4m
A biopharmaceutical company, develops and commercializes medicines in the United States.
TBPH
US$16.71
7D
2.1%
1Y
57.3%
CorMedix
Market Cap: US$679.4m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$8.67
7D
-1.1%
1Y
-36.2%
Abeona Therapeutics
Market Cap: US$322.0m
A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
ABEO
US$5.65
7D
5.4%
1Y
-5.8%
Compugen
Market Cap: US$192.0m
A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
CGEN
US$1.99
7D
1.5%
1Y
20.6%
Oramed Pharmaceuticals
Market Cap: US$154.3m
Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
ORMP
US$3.79
7D
2.4%
1Y
76.3%
Vaxart
Market Cap: US$135.7m
A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.
VXRT
US$0.57
7D
-3.6%
1Y
-7.4%